DBV jumps on peanut allergy data

DBV Technologies (Euronext:DBV) jumped EUR 5.82 (23%) to EUR 31.24 on Tuesday after reporting Phase IIb data for Viaskin Peanut ( DBV-712) on Monday. At the high dose of 250 ug, Viaskin Peanut met its primary endpoint of desensitizing significantly more patients with peanut allergies after 12 months vs. placebo (p=0.0108).

DBV evaluated 50, 100 and 250 ug Viaskin Peanut patches applied daily for 24 hours. Among those receiving the high dose, 50% responded to treatment vs. 25% receiving placebo. DBV said full results will be presented at future meetings. The company plans to start Phase III testing in about 12-18 months. ...